CI

At a glance

ClinicalIndex Comparison Record
N/ACompleted· 216 enrolled
Drug / intervention
Paritaprevir/ritonavir/ombitasvir +2 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT02725866
NCT02725866N/ACompleted
CompareCT.gov

Real World Evidence of the Effectiveness of Paritaprevir/r - Ombitasvir, ± Dasabuvir, ± Ribavirin in Participants With Chronic Hepatitis C - An Observational Study in Greece

AbbVie·observational·Posted Apr 1, 2016·Updated Mar 15, 2019

In Brief

An observational study evaluating Paritaprevir/ritonavir/ombitasvir, Dasabuvir, and 1 other intervention for Chronic Hepatitis C. Completed, enrolled 216 participants.

Detailed Summary

The interferon-free combination regimen of paritaprevir/ritonavir/ombitasvir with or without dasabuvir (ABBVIE REGIMEN) ± ribavirin (RBV) for the treatment of chronic hepatitis C (CHC) has been shown to be safe and effective in randomized controlled clinical trials with strict inclusion and exclusion criteria under well-controlled conditions. This observational study is the first effectiveness research examining the ABBVIE REGIMEN ± RBV, used according to the local label, under real-world conditions in Greece in a clinical practice patient population.

Study Details

Study Typeobservational
Allocation--
Masking--
Primary Purpose--
ConditionsChronic Hepatitis C
Countries--
Collaborators--

Timeline

N/ACompletedFinished
20162017201820192020202120222023202420252026
First PostedApr 1, 2016
Enrollment StartApr 5, 2016
Primary CompletionOct 31, 2017
TodayJul 2, 2026
Enrollment to primary: 1.6 yearsPosted 10.3 years ago

Interventions

Paritaprevir/ritonavir/ombitasvirdrug

Co-formulated tablet

Dasabuvirdrug

Tablet

Ribavirindrug

Tablet